Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma

M. Cavo, L. Pantani, A. Pezzi, M. T. Petrucci, F. Patriarca, F. Di Raimondo, G. Marzocchi, M. Galli, V. Montefusco, E. Zamagni, B. Gamberi, P. Tacchetti, A. Brioli, A. Palumbo, P. Sonneveld

Research output: Contribution to journalArticle

27 Citations (Scopus)
Original languageEnglish
Pages (from-to)2429-2431
Number of pages3
JournalLeukemia
Volume29
Issue number12
DOIs
Publication statusPublished - Dec 1 2015

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. / Cavo, M.; Pantani, L.; Pezzi, A.; Petrucci, M. T.; Patriarca, F.; Di Raimondo, F.; Marzocchi, G.; Galli, M.; Montefusco, V.; Zamagni, E.; Gamberi, B.; Tacchetti, P.; Brioli, A.; Palumbo, A.; Sonneveld, P.

In: Leukemia, Vol. 29, No. 12, 01.12.2015, p. 2429-2431.

Research output: Contribution to journalArticle

Cavo, M, Pantani, L, Pezzi, A, Petrucci, MT, Patriarca, F, Di Raimondo, F, Marzocchi, G, Galli, M, Montefusco, V, Zamagni, E, Gamberi, B, Tacchetti, P, Brioli, A, Palumbo, A & Sonneveld, P 2015, 'Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma', Leukemia, vol. 29, no. 12, pp. 2429-2431. https://doi.org/10.1038/leu.2015.274
Cavo, M. ; Pantani, L. ; Pezzi, A. ; Petrucci, M. T. ; Patriarca, F. ; Di Raimondo, F. ; Marzocchi, G. ; Galli, M. ; Montefusco, V. ; Zamagni, E. ; Gamberi, B. ; Tacchetti, P. ; Brioli, A. ; Palumbo, A. ; Sonneveld, P. / Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. In: Leukemia. 2015 ; Vol. 29, No. 12. pp. 2429-2431.
@article{5f95221004054c718cae0446415dabdf,
title = "Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma",
author = "M. Cavo and L. Pantani and A. Pezzi and Petrucci, {M. T.} and F. Patriarca and {Di Raimondo}, F. and G. Marzocchi and M. Galli and V. Montefusco and E. Zamagni and B. Gamberi and P. Tacchetti and A. Brioli and A. Palumbo and P. Sonneveld",
year = "2015",
month = "12",
day = "1",
doi = "10.1038/leu.2015.274",
language = "English",
volume = "29",
pages = "2429--2431",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma

AU - Cavo, M.

AU - Pantani, L.

AU - Pezzi, A.

AU - Petrucci, M. T.

AU - Patriarca, F.

AU - Di Raimondo, F.

AU - Marzocchi, G.

AU - Galli, M.

AU - Montefusco, V.

AU - Zamagni, E.

AU - Gamberi, B.

AU - Tacchetti, P.

AU - Brioli, A.

AU - Palumbo, A.

AU - Sonneveld, P.

PY - 2015/12/1

Y1 - 2015/12/1

UR - http://www.scopus.com/inward/record.url?scp=84951567534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951567534&partnerID=8YFLogxK

U2 - 10.1038/leu.2015.274

DO - 10.1038/leu.2015.274

M3 - Article

C2 - 26442610

AN - SCOPUS:84951567534

VL - 29

SP - 2429

EP - 2431

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 12

ER -